Pediatric PET/MR Image Registry
3 other identifiers
observational
100
1 country
1
Brief Summary
The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2018
CompletedFirst Submitted
Initial submission to the registry
March 2, 2018
CompletedFirst Posted
Study publicly available on registry
March 8, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
February 9, 2026
February 1, 2026
8.9 years
March 2, 2018
February 5, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Number of tumors
Number of tumors detected on whole body MRI, PET/MR and (if available) PET/CT scans.
up to 12 months
Secondary Outcomes (1)
Metabolic activity of tumors
up to 12 months
Study Arms (1)
Image Registry
patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
Interventions
undergo PET/MR imaging
Eligibility Criteria
Pediatric and young adult (\<40 years) male or female subjects with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor
You may qualify if:
- Patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor.
- We might also include some patients with leukemia if there is concern for a focal lesion in any of their organs.
- Participant's parents (if participant is under 18) or the participant (if participant is 18 years or older) must willingly give written informed consent prior to any image transfer to the image registry.
You may not qualify if:
- Patient has contraindications for MRI or PET/MR. This includes patients with cardiac pacemakers or intracranial vascular clips as well as patients with a blood glucose level \> 200 mg/dl.
- Lack of parental permission (if participant is younger than 18) or lack of informed consent (if participant is at least 18 years of age).
- Patient has a CNS primary tumor.
- Pregnant women and fetuses
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Stanford Universitylead
- National Cancer Institute (NCI)collaborator
Study Sites (1)
Stanford University, School of Medicine
Palo Alto, California, 94304, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Heike Daldrup-Link, MD
Stanford University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 2, 2018
First Posted
March 8, 2018
Study Start
February 1, 2018
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
February 9, 2026
Record last verified: 2026-02